Solution designed to accelerate the process of matching patients with eligible clinical trials.
Belong.Life has officially launched Tara, a SaaS-based conversational AI cancer clinical trial matching platform for health providers and contract research organizations (CROs). According to the company, Tara is designed to accelerate the process of matching patients with eligible clinical trials, enabling increased recruitment at significantly lower costs. Following the launch of Dave, Tara is Belong’s second AI Health Mentor suite of solutions.
"Since our founding, Belong has provided clinical trial matching services to more than 30,000 patients," said Eliran Malki, CEO, co-founder, Belong.Life, in a company press release. "Tara is a natural extension of our services, helping to optimize clinical trial matching to benefit stakeholders with increased patient recruitment, improved randomization, and reduced costs and logistical challenges. Tara will enable more patients around the world to access clinical trials."
Reference: Belong.Life Launches New Conversational AI SaaS Solution for Cancer Clinical Trial Matching and Recruitment. PR Newswire. September 13, 2023. Accessed September 14, 2023. https://www.prnewswire.com/news-releases/belonglife-launches-new-conversational-ai-saas-solution-for-cancer-clinical-trial-matching-and-recruitment-301926197.html
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.